Clinical Trials
52 trialsClinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
HitGen Inc.
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Shanghai Henlius Biotech
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
BJ Bioscience, Inc.
Phase 1 First-in-human Study of JS014
Anwita Biosciences
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
GEN602
Genzada Pharmaceuticals USA, Inc.
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
Suzhou Kebo Ruijun Biotechnology Co., Ltd
Study of F527 in Patients With Relapsed or Refractory Lymphoma
Shandong New Time Pharmaceutical Co., LTD
A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
Jiangsu HengRui Medicine Co., Ltd.
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
GB226
Genor Biopharma Co., Ltd.
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
iCell Gene Therapeutics
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CD5CAR-T
iCell Gene Therapeutics
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
ToTem
University College, London
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Chinese PLA General Hospital
MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma
Peking University
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
Sinocelltech Ltd.
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
ChineseAMS
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Henan Cancer Hospital
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
National Cancer Centre, Singapore
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
Guangdong Provincial People's Hospital
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Milton S. Hershey Medical Center
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
EECPL
Sinobioway Cell Therapy Co., Ltd.
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Wuxi No. 4 People's Hospital
CD19-redirected Autologous Cells (CAR-CD19 T Cells)
RenJi Hospital
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Second People's Hospital
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Alaunos Therapeutics
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
National Cancer Institute (NCI)